KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Short-term Investments (2023 - 2025)

Thermo Fisher Scientific's Short-term Investments history spans 10 years, with the latest figure at $253.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments fell 83.79% year-over-year to $253.0 million, compared with a TTM value of $253.0 million through Dec 2025, down 83.79%, and an annual FY2025 reading of $253.0 million, down 83.79% over the prior year.
  • Short-term Investments for Q4 2025 was $253.0 million at Thermo Fisher Scientific, down from $1.6 billion in the prior quarter.
  • The five-year high for Short-term Investments was $2.0 billion in Q3 2024, with the low at $3.0 million in Q4 2023.
  • Average Short-term Investments over 3 years is $1.4 billion, with a median of $1.8 billion recorded in 2024.
  • Year-over-year, Short-term Investments soared 51933.33% in 2024 and then tumbled 83.79% in 2025.
  • Tracing TMO's Short-term Investments over 3 years: stood at $3.0 million in 2023, then soared by 51933.33% to $1.6 billion in 2024, then tumbled by 83.79% to $253.0 million in 2025.
  • Per Business Quant, the three most recent readings for TMO's Short-term Investments are $253.0 million (Q4 2025), $1.6 billion (Q3 2025), and $1.8 billion (Q2 2025).